menu
    • menu
    [{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HST-003","moa":"Hyaline cartilage","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quince Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Quince Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NOV004

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-Targeti...

                            Details : In preclinical studies, Quince observed a decrease in fracture healing time by 50% in NOV004 treated groups. Additionally, bone deposition and max load doubled and the force required to refracture the bones increased more than two-fold in mouse models.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 16, 2022

                            Lead Product(s) : NOV004

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Histogen

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Histogen

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HST-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

                            Details : U.S. FDA has verbally notified the company that it has additional questions about the company’s IND application package for the planned Phase 1/2 clinical trial of HST-003.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 19, 2021

                            Lead Product(s) : HST-003

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth